Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
Michishige Terasaki, Munenori Hiromura, Yusaku Mori, Kyoko Kohashi, Masaharu Nagashima, Hideki Kushima, Takuya Watanabe, Tsutomu Hirano, Michishige Terasaki, Munenori Hiromura, Yusaku Mori, Kyoko Kohashi, Masaharu Nagashima, Hideki Kushima, Takuya Watanabe, Tsutomu Hirano
Abstract
Direct associations between hyperglycemia and atherosclerosis remain unclear. We investigated the association between the amelioration of glycemia by sodium-glucose cotransporter 2 inhibitors (SGLT2is) and macrophage-driven atherosclerosis in diabetic mice. We administered dapagliflozin or ipragliflozin (1.0 mg/kg/day) for 4-weeks to apolipoprotein E-null (Apoe-/-) mice, streptozotocin-induced diabetic Apoe-/- mice, and diabetic db/db mice. We then determined aortic atherosclerosis, oxidized low-density lipoprotein (LDL)-induced foam cell formation, and related gene expression in exudate peritoneal macrophages. Dapagliflozin substantially decreased glycated hemoglobin (HbA1c) and glucose tolerance without affecting body weight, blood pressure, plasma insulin, and lipids in diabetic Apoe-/- mice. Aortic atherosclerotic lesions, atheromatous plaque size, and macrophage infiltration in the aortic root increased in diabetic Apoe-/- mice; dapagliflozin attenuated these changes by 33%, 27%, and 20%, respectively. Atherosclerotic lesions or foam cell formation highly correlated with HbA1c. Dapagliflozin did not affect atherosclerosis or plasma parameters in non-diabetic Apoe-/- mice. In db/db mice, foam cell formation increased by 4-fold compared with C57/BL6 mice, whereas ipragliflozin decreased it by 31%. Foam cell formation exhibited a strong correlation with HbA1c. Gene expression of lectin-like ox-LDL receptor-1 and acyl-coenzyme A:cholesterol acyltransferase 1 was upregulated, whereas that of ATP-binding cassette transporter A1 was downregulated in the peritoneal macrophages of both types of diabetic mice. SGLT2i normalized these gene expressions. Our study is the first to demonstrate that SGLT2i exerts anti-atherogenic effects by pure glucose lowering independent of insulin action in diabetic mice through suppressing macrophage foam cell formation, suggesting that foam cell formation is highly sensitive to glycemia ex vivo.
Conflict of interest statement
Competing Interests: This study was financially supported from AstraZeneca and Astellas Pharma Inc. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Figures
References
- Allahverdian S, Pannu PS, Francis GA. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc Res. 2012; 95: 165–172. 10.1093/cvr/cvs094
- Lusis AJ. Atherosclerosis. Nature. 2000; 407: 233–241.
- Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001; 104: 503–516.
- Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353:2643–2653.
- Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52: 2288–2298. 10.1007/s00125-009-1470-0
- Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia?. Journal of Lipid Research. 2009; 50 (supplement): S335–339.
- Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010; 55: 1310–1317. 10.1016/j.jacc.2009.10.060
- Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of lomgitudinal studies. J Am Coll Cardiol. 2007; 49: 403–414.
- Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Rinfret S, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 56: 1113–1132. 10.1016/j.jacc.2010.05.034
- Chen GP, Zhang XQ, Wu T, Li L, Han J, Du CQ. Alteration of mevalonate pathway in proliferated vascular smooth muscle from diabetic mice: possible role in high-glucose-induced atherogenic process. J Diabetes Res. 2015: 379287 10.1155/2015/379287
- Mudaliar H, Pollock C, Ma J, Wu H, Chadban S, Panchapakesan U. The role of TLR2 and 4-mediated inflammatory pathways in endothelial cells exposed to high glucose. PLoS One. 2014; 9: e108844 10.1371/journal.pone.0108844
- Hamuro M, Polan J, Natarajan M, Mohan S. High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis. 2002; 162: 277–287.
- Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospets. Nat Rev Endocrinol. 2012; 8: 495–502. 10.1038/nrendo.2011.243
- DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013; 36: 3169–3176. 10.2337/dc13-0387
- Nauck MA. Update on develioments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014; 8: 1335–1380. 10.2147/DDDT.S50773
- Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig. 2014; 5: 265–275. 10.1111/jdi.12214
- Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circulation Res. 2004; 94:892–901.
- Fukuhara T, Sakai M, Sakamoto Y, Takeya M, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: one mechanism for an increased rate of atherosclerosis in diabetes. J Bio Chem. 2005; 280, 3355–3364.
- Chang YC, Sheu WH, Chien YS, Tseng PC, Lee WJ, Chiang AN. Hyperglycemia accelerates ATP-binding cassette transporter A1 degradation via an ERK-dependent pathway in macrophages. Journal of Cellular Biochemistry. 2013; 114:1364–1373. 10.1002/jcb.24478
- Mauerer R, Ebert S, Langmann T. High glucose, unsaturated and saturated fatty acids differentially regulate expression of ATP-binding cassette transporters ABCA1 and ABCG1 in human macrophages. Exp Mol Med. 2009; 41:126–132.
- Takeda Y, Fujita Y, Honjo J, Yanagimachi T, Sakagami H, Takiyama Y, et al. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia. 2012; 55: 404–412. 10.1007/s00125-011-2365-4
- Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ. The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources. Comp Med. 2011; 61:356–360.
- Terasaki M, Nagashima M, Watanabe T, Nohtomi K, Mori Y, Miyazaki A, et al. Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism. 2012; 61:974–977. 10.1016/j.metabol.2011.11.011
- Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin’s actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One. 2013; 8: e70933 10.1371/journal.pone.0070933
- Nogi Y, Nagashima M, Terasaki M, Nohtomi K, Watanabe T, Hirano T. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS One. 2012; 7: e35683 10.1371/journal.pone.0035683
- Nagashima M, Watanabe T, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011; 54:2649–2659. 10.1007/s00125-011-2241-2
- Nagashima M, Watanabe T, Shiraishi Y, Morita R, Terasaki M, Arita S, et al. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis. 2010; 212: 70–77. 10.1016/j.atherosclerosis.2010.04.027
- Arora S, Ojha SK, Vohora D. Characterisation of Streptozotocin Induced Diabetes Mellitus in Swiss Albino Mice. Global Journal of Pharmacology. 2009; 3: 81–84.
- Merovci A, Mari A, Solis C, Xiong J, Daniele G, Chavez-Velazquez A, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124: 509–514. 10.1172/JCI70704
- Lin CS, Lin FY, Ho LJ, Tsai CS, Cheng SM, Wu WL, et al. PKCδsignaling regulates SR-A and CD36 expression and foam cell formation. Cardiovascular Res. 2012; 95: 346–355.
- Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nature Medicine. 2001; 7, 840–846.
- Kaplan M, Kerry R, Aviram M, Hayek T. High glucose concentration increases macrophage cholesterol biosynthesis in diabetes through activation of the sterol regulatory element binding protein 1 (SREBP1): inhibitory effect of insulin. J Cardiovasc Pharmacol. 2008; 52: 324–332. 10.1097/FJC.0b013e3181879d98
- Hayek T, Hussein K, Aviram M, Coleman R, Keidar S, Pavoltzky E, et al. Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose. Atherosclerosis. 2005; 183:25–33.
- Moheimani F, Tan JT, Brown BE, Heather AK, van Reyk DM, Davies MJ. Effect of exposure of human monocyte-derived macrophages to high, versus normal, glucose on subsequent lipid accumulation from glycated and acetylated low-density lipoproteins. Exp Diabetes Res 2011; 2011: 851280 10.1155/2011/851280
- Sekiya M, Osuga J, Igarashi M, Okazaki H, Ishibashi S. The role of neutral Cholesterol Ester Hydrolysis in Macrophage Foam Cells. Journal of Atherosclerosis and Trombosis. 2011; 18: 359–364.
- Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005; 1:121–131.
- Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006; 99: 1031–1043.
- Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007; 117: 2216–2224.
- Yvan-Chravet L, Wang N, Tall AR. Role of HDL, ABCA1 and ABCG1 transporters in cholesterol efflux and immune response. Atheroscler Thromb Vasc Biol. 2010; 30: 139–143.
- Machado-Lima A, Iborra RT, Pinto RS, Castilho G, Sartori CH, Oliveira ER, et al. In type 2 diabetes mellitus glycated albumin alters macrophage gene expression impairing ABCA1-mediated cholesterol efflux. J of Cellular physiology. 2015; 230: 1250–1257.
- Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, Daugherty A, et al. Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J Bio Chem. 2006; 281: 21216–21224.
- Passarelli M, Tang C, McDonald TO, O’Brien KD, Gerrity RG, Heinecke JW, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes. 2005; 54: 2198–2205.
- Patel DC, Albrecht C, Pavitt D, Paul V, Pourreyron C, Newman SP, et al. Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One. 2011; 6: e22142 10.1371/journal.pone.0022142
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414: 813–820.
- Piarulli F, Sartore G, Lapolla A. Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol. 2013; 50: 101–110. 10.1007/s00592-012-0412-3
- Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23: 599–622.
Source: PubMed